|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar
|
|
3
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Easton JB and Houghton PJ: mTOR and cancer
therapy. Oncogene. 25:6436–6446. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pópulo H, Lopes JM and Soares P: The mTOR
signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ilagan E and Manning BD: Emerging role of
mTOR in the response to cancer therapeutics. Trends Cancer.
2:241–251. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Showkat M, Beigh MA and Andrabi KI: mTOR
signaling in protein translation regulation: Implications in cancer
genesis and therapeutic interventions. Mol Biol Int.
2014:6869842014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kurgan N, Tsakiridis E, Kouvelioti R,
Moore J, Klentrou P and Tsiani E: Inhibition of human lung cancer
cell proliferation and survival by Post-exercise serum is
associated with the inhibition of Akt, mTOR, p70 S6K, and Erk1/2.
Cancers (Basel). 9. pii: E46. 2017, View Article : Google Scholar
|
|
9
|
Wang H, Duan L, Zou Z, Li H, Yuan S, Chen
X, Zhang Y, Li X, Sun H, Zha H, et al: Activation of the
PI3K/Akt/mTOR/p70S6K pathway is involved in S100A4-induced
viability and migration in colorectal cancer cells. Int J Med Sci.
11:841–849. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Holz MK: The role of S6K1 in ER-positive
breast cancer. Cell Cycle. 11:3159–3165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao J, Zhang Q, Xu J, Guo L and Li X:
Clinical significance of serum miR-21 in breast cancer compared
with CA153 and CEA. Chin J Cancer Res. 25:743–748. 2013.
|
|
12
|
Hamam R, Hamam D, Alsaleh KA, Kassem M,
Zaher W, Alfayez M, Aldahmash A and Alajez NM: Circulating
microRNAs in breast cancer: Novel diagnostic and prognostic
biomarkers. Cell Death Dis. 8:e30452017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rabinowits G, Gerçel-Taylor C, Day JM,
Taylor DD and Kloecker GH: Exosomal microRNA: A diagnostic marker
for lung cancer. Clin Lung Cancer. 10:42–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu X, Piper-Hunter MG, Crawford M, Nuovo
GJ, Marsh CB, Otterson GA and Nana-Sinkam SP: MicroRNAs in the
pathogenesis of lung cancer. J Thorac Oncol. 4:1028–1034. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Slattery ML, Lee FY, Pellatt AJ, Mullany
LE, Stevens JR, Samowitz WS, Wolff RK and Herrick JS: Infrequently
expressed miRNAs in colorectal cancer tissue and tumor molecular
phenotype. Mod Pathol. 30:1152–1169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Toyota M, Suzuki H, Sasaki Y, Maruyama R,
Imai K, Shinomura Y and Tokino T: Epigenetic silencing of
microRNA-34b/c and B-cell translocation gene 4 is associated with
CpG island meth-ylation in colorectal cancer. Cancer Res.
68:4123–4132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hermeking H: The miR-34 family in cancer
and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar
|
|
18
|
Xi L, Zhang Y, Kong S and Liang W: miR-34
inhibits growth and promotes apoptosis of osteosarcoma in nude mice
through targetly regulating TGIF2 expression. Biosci Rep. 38:pii:
BSR20180078. 2018. View Article : Google Scholar
|
|
19
|
Li XJ, Ren ZJ and Tang JH: MicroRNA-34a: A
potential therapeutic target in human cancer. Cell Death Dis.
5:e13272014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W,
Liu J, Yu J and Chen J: miRNA-96 suppresses KRAS and functions as a
tumor suppressor gene in pancreatic cancer. Cancer Res.
70:6015–6025. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cai C, Chen QB, Han ZD, Zhang YQ, He HC,
Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 inhibits
tumor progression by targeting RPS6KB1 in Human prostate cancer.
Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Janaki Ramaiah M, Lavanya A, Honarpisheh
M, Zarea M, Bhadra U and Bhadra MP: MiR-15/16 complex targets p70S6
kinase 1 and controls cell proliferation in MDA-MB-231 breast
cancer cells. Gene. 552:255–264. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dai GH, Ma PZ, Song XB, Liu N, Zhang T and
Wu B: MicroRNA-223-3p inhibits the angiogenesis of ischemic cardiac
microvascular endothelial cells via affecting RPS6KB1/hif-1a signal
pathway. PLoS One. 9:e1084682014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi ZM, Wang J, Yan Z, You YP, Li CY, Qian
X, Yin Y, Zhao P, Wang YY, Wang XF, et al: MiR-128 inhibits tumor
growth and angiogenesis by targeting p70S6K1. PLoS One.
7:e327092012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
An HJ, Kwak SY, Yoo JO, Kim JS, Bae IH,
Park MJ, Cho MY, Kim J and Han YH: Novel miR-5582-5p functions as a
tumor suppressor by inducing apoptosis and cell cycle arrest in
cancer cells through direct targeting of GAB1, SHC1, and CDK2.
Biochim Biophys Acta. 1862:1926–1937. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choe MH, Yoon Y, Kim J, Hwang SG, Han YH
and Kim JS: miR-550a-3-5p acts as a tumor suppressor and reverses
BRAF inhibitor resistance through the direct targeting of YAP. Cell
Death Dis. 9:6402018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kwak SY, Yoo JO, An HJ, Bae IH, Park MJ,
Kim J and Han YH: miR-5003-3p promotes epithelial-mesenchymal
transition in breast cancer cells through Snail stabilization and
direct targeting of E-cadherin. J Mol Cell Biol. Jun 9–2016.Epub
ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoo JO, Kwak SY, An HJ, Bae IH, Park MJ
and Han YH: miR-181b-3p promotes epithelial-mesenchymal transition
in breast cancer cells through Snail stabilization by directly
targeting YWHAG. Biochim Biophys Acta. 1863:1601–1611. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kozomara A and Griffiths-Jones S: miRBase:
Integrating microRNA annotation and deep-sequencing data. Nucleic
Acids Res. 39(Database Issue): D152–D157. 2011. View Article : Google Scholar :
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
32
|
Sato T, Stange DE, Ferrante M, Vries RG,
Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J,
Siersema PD and Clevers H: Long-term expansion of epithelial
organoids from human colon, adenoma, adenocarcinoma, and Barrett's
epithelium. Gastroenterology. 141:1762–1772. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Grabinger T, Luks L, Kostadinova F,
Zimberlin C, Medema JP, Leist M and Brunner T: Ex vivo culture of
intestinal crypt organoids as a model system for assessing cell
death induction in intestinal epithelial cells and enteropathy.
Cell Death Dis. 5:e12282014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vlachos IS, Kostoulas N, Vergoulis T,
Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD,
Prionidis K, Dalamagas T and Hatzigeorgiou AG: DIANA miRPath v20:
Investigating the combinatorial effect of microRNAs in pathways.
Nucleic Acids Res. 40:W498–W504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
36
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43(Database Issue): D146–D152. 2015. View Article : Google Scholar :
|
|
37
|
Park SY, Lee JH, Ha M, Nam JW and Kim VN:
miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat
Struct Mol Biol. 16:23–29. 2009. View Article : Google Scholar
|
|
38
|
Shaheen S, Ahmed M, Lorenzi F and Nateri
AS: Spheroid-formation (Colonosphere) assay for in vitro assessment
and expansion of stem cells in colon cancer. Stem Cell Rev.
12:492–499. 2016. View Article : Google Scholar :
|
|
39
|
Shimono Y, Mukohyama J, Isobe T, Johnston
DM, Dalerba P and Suzuki A: Organoid culture of human cancer stem
cells. Methods Mol Biol. Sep 22–2016.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Crespo M, Vilar E, Tsai SY, Chang K, Amin
S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, et
al: Colonic organoids derived from human induced pluripotent stem
cells for modeling colorectal cancer and drug testing. Nat Med.
23:878–884. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hubert CG, Rivera M, Spangler LC, Wu Q,
Mack SC, Prager BC, Couce M, McLendon RE, Sloan AE and Rich JN: A
Three-dimensional organoid culture system derived from human
glioblastomas recapitulates the hypoxic gradients and cancer stem
cell heterogeneity of tumors found in vivo. Cancer Res.
76:2465–2477. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Thompson EW, Newgreen DF and Tarin D:
Carcinoma invasion and metastasis: A role for
epithelial-mesenchymal transition? Cancer Res. 65:5991–5995. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Amaral CL, Freitas LB, Tamura RE, Tavares
MR, Pavan IC, Bajgelman MC and Simabuco FM: S6Ks isoforms
contribute to viability, migration, docetaxel resistance and tumor
formation of prostate cancer cells. BMC Cancer. 16:6022016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fu YP, Edvardsen H, Kaushiva A, Arhancet
JP, Howe TM, Kohaar I, Porter-Gill P, Shah A, Landmark-Høyvik H,
Fosså SD, et al: NOTCH2 in breast cancer: Association of SNP
rs11249433 with gene expression in ER-positive breast tumors
without TP53 mutations. Mol Cancer. 9:1132010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ekim B, Magnuson B, Acosta-Jaquez HA,
Keller JA, Feener EP and Fingar DC: mTOR kinase domain
phosphorylation promotes mTORC1 signaling, cell growth, and cell
cycle progression. Mol Cell Biol. 31:2787–2801. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Danielsen SA, Eide PW, Nesbakken A, Guren
T, Leithe E and Lothe RA: Portrait of the PI3K/AKT pathway in
colorectal cancer. Biochim Biophys Acta. 1855:104–121. 2015.
|
|
47
|
Zhang T, Ma Y, Fang J, Liu C and Chen L: A
deregulated PI3K-AKT signaling pathway in patients with colorectal
cancer. J Gastrointest Cancer. 50:35–41. 2019. View Article : Google Scholar
|
|
48
|
Johnson SM, Gulhati P, Rampy BA, Han Y,
Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression
patterns of PI3K/Akt/mTOR signaling pathway components in
colorectal cancer. J Am Coll Surg. 210:767–778. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Crowell JA, Steele VE and Fay JR:
Targeting the AKT protein kinase for cancer chemoprevention. Mol
Cancer Ther. 6:2139–2148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bitting RL and Armstrong AJ: Targeting the
PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Endocr Relat Cancer. 20:R83–R99. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hassan B, Akcakanat A, Holder AM and
Meric-Bernstam F: Targeting the PI3-kinase/Akt/mTOR signaling
pathway. Surg Oncol Clin N Am. 22:641–664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Soliman GA: The role of mechanistic target
of rapamycin (mTOR) complexes signaling in the immune responses.
Nutrients. 5:2231–2257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li D, Liu X, Lin L, Hou J, Li N, Wang C,
Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits
hepatocellular carcinoma growth and correlates with prognosis of
patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang X, Shi H, Tang H, Fang Z, Wang J and
Cui S: miR-218 inhibits the invasion and migration of colon cancer
cells by targeting the PI3K/Akt/mTOR signaling pathway. Int J Mol
Med. 35:1301–1308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu C, Zeng Q, Xu W, Jiao L, Chen Y, Zhang
Z, Wu C, Jin T, Pan A, Wei R, et al: miRNA-100 inhibits human
bladder urothe-lial carcinogenesis by directly targeting mTOR. Mol
Cancer Ther. 12:207–219. 2013. View Article : Google Scholar
|
|
56
|
Fornari F, Milazzo M, Chieco P, Negrini M,
Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L and Gramantieri
L: MiR-199a-3p regulates mTOR and c-Met to influence the
doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res.
70:5184–5193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen W, Zhao X, Dong Z, Cao G and Zhang S:
Identification of microRNA profiles in salivary adenoid cystic
carcinoma cells during metastatic progression. Oncol Lett.
7:2029–2034. 2014. View Article : Google Scholar : PubMed/NCBI
|
